The risk of deep venous thrombosis and pulmonary embolism in giant cell arteritis: A general population-based study

Annals of the Rheumatic Diseases

Volumn 75, Issue 1, 2016, Pages 148-154

  Aviña Zubieta, J Antonio ^a   Bhole, Vidula M ^a   Amiri, Neda ^a   Sayre, Eric C ^a   Choi, Hyon K ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; GLUCOCORTICOID;

AGED; ARTICLE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FEMALE; GIANT CELL ARTERITIS; HIGH RISK POPULATION; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; INCIDENCE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TREND STUDY; BRITISH COLUMBIA; CASE CONTROL STUDY; COMPLICATION; PROCEDURES; PULMONARY EMBOLISM; SENSITIVITY AND SPECIFICITY; VENOUS THROMBOSIS;

AGED; BRITISH COLUMBIA; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GIANT CELL ARTERITIS; HUMANS; INCIDENCE; MALE; PULMONARY EMBOLISM; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VENOUS THROMBOSIS;

EID: 84954238172     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-205665     Document Type: Article

References (42)

1. Borchers AT, Gershwin ME. Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment. Autoimmun Rev 2012;11: A544-54.
2. Liozon E, Herrmann F, Ly K, et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 2001;111:211-17.
3. Robson JC, Kiran A, Maskell J, et al. The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. Ann Rheum Dis 2015;74:129-35.
4. Martin JF, Kittas C, Triger DR. Giant cell arteritis of coronary arteries causing myocardial infarction. Brit Heart J 1980;43:487-9.
5. Godoy P, Araujo de SA, Paulino E Jr, et al. Coronary giant cell arteritis and acute myocardial infarction. Arq Bras Cardiol 2007;88:e84-7.
6. Tomasson G, Peloquin C, Mohammad A, et al. Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. Ann Intern Med 2014;160:73-80.
7. Lu-Emerson C, Walker M, Huber BR, et al. Lethal giant cell arteritis with multiple ischemic strokes despite aggressive immunosuppressive therapy. J Neurol Sci 2010;295:120-4.
8. Fitzgerald AJ, Ironside JW, Summers DM, et al. Two cases of recurrent stroke in treated giant cell arteritis: diagnostic and therapeutic dilemmas. J Clin Rheumatol 2010;16:225-8.
9. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003;107(23 Suppl 1):I9-16.
10. Xu J, Lupu F, Esmon CT. Inflammation, innate immunity and blood coagulation. Hamostaseologie 2010;30:5-6, 8-9.
11. Lee MS, Smith SD, Galor A, et al. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 2006;54:3306-9.
12. Foroozan R, Danesh-Meyer H, Savino PJ, et al. Thrombocytosis in patients with biopsy-proven giant cell arteritis. Ophthalmology 2002;109:1267-71.
13. Price N, Clearkin LG. Thrombocytosis and giant cell arteritis. Lancet 1994; 343:672.
14. Krishna R, Kosmorsky GS. Implications of thrombocytosis in giant cell arteritis. Am J Ophthalmol 1997;124:103.
15. Costello F, Zimmerman MB, Podhajsky PA, et al. Role of thrombocytosis in diagnosis of giant cell arteritis and differentiation of arteritic from non-arteritic anterior ischemic optic neuropathy. Eur J Ophthalmol 2004;14:245-57.
16. Zoller B, Li X, Sundquist J, et al. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 2012;379:244-9.
17. Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5:692-9.
18. Solomon DH, Massarotti E, Garg R, et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011;305:2525-31.
19. Avina-Zubieta JA, Abrahamowicz M, De Vera MA, et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford) 2013;52:68-75.
20. Etminan M, Forooghian F, Brophy JM, et al. Oral fluoroquinolones and the risk of retinal detachment. JAMA 2012;307:1414-9.
21. De Vera MA, Choi H, Abrahamowicz M, et al. Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 2011;70:1020-4.
22. Aviña-Zubieta JA, Abrahamowicz M, Choi HK, et al. Risk of cerebrovascular disease associated with the use of glucocorticoids in patients with incident rheumatoid arthritis. Ann Rheum Dis 2011;70:990-5.
23. Durand M, Thomas SL. Incidence of infections in patients with giant cell arteritis: a cohort study. Arthritis Care Res 2012;64:581-8.
24. Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990-2001. Ann Rheum Dis 2006;65:1093-8.
25. Huerta C, Johansson S, Wallander MA, et al. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007;167:935-43.
26. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
27. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993;46:1075-9; discussion 81-90.
28. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695-706.
29. Cox D. Regression models and life-tables. J R Stat Soc Series B Stat Methodol 1972;34:187-220.
30. Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol 2009;170:244-56.
31. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006;15:291-303.
32. Martínez-Taboada VM, López-Hoyos M, Narvaez J, et al. Effect of antiplatelet/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: a cumulative meta-analysis. Autoimmun Rev 2014;13:788-94.
33. Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 1998;41:1497-504.
34. Warrington K, Jarpa E, Crowson C, et al. Increased risk of peripheral arterial disease in polymyalgia rheumatica: a population-based cohort study. Arthritis Res Ther 2009;11:R50.
35. Virchow RLK. Thrombose und embolie. Massachusetts: Science History Publications, 1998.
36. Borensztajn KS, von der Thusen JH, Spek CA. The role of coagulation in chronic inflammatory disorders: a jack of all trades. Curr Pharm Des 2011;17:9-16.
37. Previtali E, Bucciarelli P, Passamonti SM, et al. Risk factors for venous and arterial thrombosis. Blood Transfus 2011;9:120-38.
38. Seriolo B, Cutolo M, Garnero A, et al. Risk factors for thrombotic events in giant cell arteritis and polymyalgia rheumatica. Br J Rheumatol 1998;37:1251-3.
39. Manna R, Latteri M, Cristiano G, et al. Anticardiolipin antibodies in giant cell arteritis and polymyalgia rheumatica: a study of 40 cases. Br J Rheumatol 1998;37:208-10.
40. Johannesdottir SA, Horvath-Puho E, Dekkers OM, et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med 2013;173:743-52.
41. Maradit Kremers H, Reinalda MS, Crowson CS, et al. Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum 2007;57:279-86.
42. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 2003;139:505-15.